<DOC>
	<DOCNO>NCT01457170</DOCNO>
	<brief_summary>The purpose study determine effect Apelin lung circulation . The investigator hypothesise Apelin relax lung blood vessel improve pump ability heart .</brief_summary>
	<brief_title>Effects Apelin Lung Circulation Pulmonary Hypertension</brief_title>
	<detailed_description>Apelin endogenous peptide physiological action cardiovascular system abundantly express pulmonary vasculature . Pre-clinical model preliminary clinical data indicate Apelin deficiency may mediate contribute pathogenesis pulmonary hypertension heart failure . Apelin cause peripheral vasodilatation increase cardiac contractility . The investigator determine effect Apelin pulmonary circulation 3 group ; healthy control , people pulmonary arterial hypertension people pulmonary hypertension due heart failure . Each subject receive Apelin infusion saline placebo infusion crossover design . The infusion give random order subject investigator blind . The investigator hypothesise Apelin mark pulmonary haemodynamic effect observe systemic circulation . Moreover , investigator propose Apelin mark vasodilatory effect human pulmonary vasculature reduce pulmonary vascular resistance patient pulmonary arterial hypertension pulmonary hypertension due leave heart disease .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>PULMONARY ARTERIAL HYPERTENSION Pulmonary Arterial Hypertension Idiopathic , Heritable , associate connective tissue disease associate drugs/toxins mean pulmonary artery pressure &gt; /= 25mmHg pulmonary capillary wedge pressure &lt; 15 mmHg normal/reduced cardiac output stable WHO functional class II IV significant leave ventricular dysfunction chronic lung disease ( FEV1 &lt; 60 % abnormal CT ) chronic thromboembolic pulmonary hypertension HEART FAILURE stable treatment 3 month prior study NYHA grade II IV ejection fraction &lt; 35 % , leave ventricular enddiastolic diameter &gt; 5.5 cm and/or shorten fraction &lt; 20 % Tricuspid regurgitant velocity &gt; /= 3.0 m/s HEALTHY VOLUNTEERS mean pulmonary artery pressure &lt; 25 mmHg tricuspid regurgitant velocity &lt; 2.5 m/s obstructive coronary artery disease ALL SUBJECTS bleed diathesis woman childbearing potential without pregnancy test systolic blood pressure &gt; 190 mmHg &lt; 100 mmHg malignant arrhythmias renal hepatic failure haemodynamically significant valvular heart disease severe significant comorbidity pacemaker already take part another trial lack informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Apelin</keyword>
	<keyword>Haemodynamics</keyword>
	<keyword>pulmonary vascular resistance</keyword>
	<keyword>cardiac output</keyword>
</DOC>